Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | CNR1 | P21554 | 3/20 | 0.54 |
| ▸ | CNR2 | P34972 | 9/20 | 0.52 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.48 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3095071 | 0.86 | CNR2 (0.54) | CNR1CNR2 | |
| SCHEMBL3084315 | 0.86 | CNR2 (0.54) | CNR1CNR2 | |
| SCHEMBL3083040 | 0.84 | KDM4E (0.56) | KDM4EMEN1MAPTMAPK1KMT2A | |
| SCHEMBL923180 | 0.84 | CNR2 (0.71) | CNR1CNR2 | |
| SCHEMBL29838956 | 0.84 | CNR2 (0.71) | CNR1CNR2 | |
| SCHEMBL12907707 | 0.82 | CNR1 (0.66) | KDM4EMEN1MAPTMAPK1KMT2A | |
| SCHEMBL24225739 | 0.81 | KDM4E (0.68) | KDM4EMEN1MAPTMAPK1KMT2A | |
| SCHEMBL13955262 | 0.81 | KDM4E (0.68) | KDM4EMEN1MAPTMAPK1KMT2A | |
| SCHEMBL4612450 | 0.81 | CNR1 (0.67) | KDM4EMEN1MAPTMAPK1KMT2A | |
| SCHEMBL662250 | 0.81 | CNR1 (0.65) | KDM4EMEN1MAPTMAPK1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4395801-A1 | USE OF AN EXTRACT OF MYROTHAMNUS SP FOR PROMOTING HAIR GROWTH | Lubrizol Advanced Materials, Inc. (US) | 2024-07-10 | — | — | EP | disclosed |
| EP-4359121-A1 | RESIN CONTAINING AQUEOUS INKJET INK AND RECORDING METHOD | AGFA NV (BE) | 2024-05-01 | — | — | EP | disclosed |
| EP-4340807-A1 | HAIR COLOR COMPOSITIONS FOR MITIGATING COLOR LOSS | Lubrizol Advanced Materials, Inc. (US) | 2024-03-27 | — | — | EP | disclosed |
| WO-2023031730-A1 | USE OF AN EXTRACT OF MYROTHAMNUS SP FOR PROMOTING HAIR GROWTH | LUBRIZOL ADVANCED MATERIALS, INC. (US) | 2023-03-09 | — | — | WO | disclosed |
| WO-2022268645-A1 | RESIN CONTAINING AQUEOUS INKJET INK AND RECORDING METHOD | AGFA NV (BE) | 2022-12-29 | — | — | WO | disclosed |
| US-20210154120-A1 | HAIR MODIFICATION COMPOSITION AND METHOD THEREFOR | LUBRIZOL ADVANCED MATERIALS, INC. (US) | 2021-05-27 | — | — | US | disclosed |
| EP-3773458-A1 | HAIR MODIFICATION COMPOSITION AND METHOD THEREFOR | Lubrizol Advanced Materials, Inc. (US) | 2021-02-17 | — | — | EP | disclosed |
| WO-2019200027-A1 | HAIR MODIFICATION COMPOSITION AND METHOD THEREFOR | LUBRIZOL ADVANCED MATERIALS, INC. (US) | 2019-10-17 | — | — | WO | disclosed |
| EP-2953610-B1 | SEMI-PERMANENT HAIR STRAIGHTENING COMPOSITION AND METHOD | LUBRIZOL ADVANCED MAT INC (US) | 2019-04-10 | — | — | EP | disclosed |
| US-9931290-B2 | Acrylate copolymer thickeners | LUBRIZOL ADVANCED MATERIALS, INC. (US) | 2018-04-03 | — | — | US | disclosed |
| US-20130189198-A1 | Acrylate Copolymer Thickeners | LUBRIZOL ADVANCED MATERIALS, INC. (US) | 2013-07-25 | — | — | US | disclosed |
| US-20130183361-A1 | STRUCTURED ACRYLATE COPOLYMER FOR USE IN MULTI-PHASE SYSTEMS | LUBRIZOL ADVANCED MATERIALS, INC. (US) | 2013-07-18 | — | — | US | disclosed |
| US-20130115185-A1 | Structured Acrylate Copolymer Thickeners | LUBRIZOL ADVANCED MATERIALS, INC. (US) | 2013-05-09 | — | — | US | disclosed |
| US-20130101543-A1 | Blends Of Acrylic Copolymer Thickeners | LUBRIZOL ADVANCED MATERIALS, INC. (US) | 2013-04-25 | — | — | US | disclosed |
| US-7803799-B2 | such as 1-(2,4-dichlorophenyl)-N-(piperidin-1-yl)-5-(selenophen-2-yl)-1H-pyrazole-3-carboxamide, used for treating cannabinoid-receptor mediated disorders selected from obesity, metabolic syndrome, drug abuse and dependence or neuropathic pain | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2010-09-28 | — | — | US | disclosed |
| US-7799321-B2 | Color cosmetic compositions | ISP INVESTMENTS INC. (US) | 2010-09-21 | — | — | US | disclosed |
| US-7705024-B2 | Oxadiazole compounds | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2010-04-27 | — | — | US | disclosed |
| US-20080255211-A1 | Oxadiazole Compounds | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2008-10-16 | — | — | US | disclosed |
| US-20080021031-A1 | SELENOPHENE COMPOUNDS | NATIONAL HEALTH RESEARCH INSTITUTE (TW) | 2008-01-24 | — | — | US | disclosed |
| US-20070231286-A1 | Color cosmetic compositions | ISP INVESTMENTS INC. | 2007-10-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080021031-A1 | SELENOPHENE COMPOUNDS | CNR2, CNR1, SELENOI | KDM4E 1250/4885MEN1 1271/4885MAPT 595/4885 |
| US-20080255211-A1 | Oxadiazole Compounds | CNR1, CNR2, OPRD1 | KDM4E 2511/4885MEN1 3156/4885MAPT 2111/4885 |
| US-20210154120-A1 | HAIR MODIFICATION COMPOSITION AND METHOD THEREFOR | DSC1, HADHB, PHOSPHO1 | KDM4E 1636/4885MEN1 748/4885MAPT 1306/4885 |
| US-20130101543-A1 | Blends Of Acrylic Copolymer Thickeners | ABHD16A, DSG1, ALAD | KDM4E 3743/4885MEN1 1573/4885MAPT 1339/4885 |
| US-20130189198-A1 | Acrylate Copolymer Thickeners | ACR, RAD51, ABHD16A | KDM4E 4022/4885MEN1 2860/4885MAPT 1054/4885 |
| US-20130183361-A1 | STRUCTURED ACRYLATE COPOLYMER FOR USE IN MULTI-PHASE SYSTEMS | ALG1, PARG, CUTA | KDM4E 3557/4885MEN1 1461/4885MAPT 285/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.